Replies to post #71284 on Biotech Values

[ghmm]

Intermune's data is out very impressive. Sorry no link yet. I'll let you post it when it comes out

Median Change

HCV RNA at
EOT(1),(2) BLQ BLD
Log10 (25 IU/mL) (9.3 IU/mL)
Dose N (IU/mL) (%) (%)
Placebo 12 -2.2 1/12 (8%) 0/12 (0%)
100 mg q8h 8 -5.5 6/8 (75%) 1/8 (13%)
200 mg q8h 8 -5.7 7/8 (88%) 4/8 (50%)
300 mg q8h 7 -5.6 5/7 (71%) 4/7 (57%)
400 mg q12h 7 -4.7 4/7 (57%) 1/7 (14%)
600 mg q12h 8 -5.4 6/8 (75%) 1/8 (13%)
900 mg q12h 7 -5.3 4/7 (57%) 1/7 (14%)



Is it coincidence that the two reported news today?

[genisi]

patients will be enrolled as two cohorts, with randomization of the second larger cohort being initiated based on 12 week safety data of the first cohort.

I guess that this kind of conditioned enrollment reflects the FDA's worry over safety and will slow the trial.

[ghmm]

VRUS, Roche Start Phase-2b Trial of R7128

AM I misreading something or is Roche also testing lower doses of PEG in this study (4, 5 and 6)?
http://clinicaltrials.gov/ct2/show/NCT00517439